5255-96-9Relevant academic research and scientific papers
3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts
Brnardic, Edward J.,Fraley, Mark E.,Garbaccio, Robert M.,Layton, Mark E.,Sanders, John M.,Culberson, Chris,Jacobson, Marlene A.,Magliaro, Brian C.,Hutson, Pete H.,O'Brien, Julie A.,Huszar, Sarah L.,Uslaner, Jason M.,Fillgrove, Kerry L.,Tang, Cuyue,Kuo, Yuhsin,Sur, Sylvie M.,Hartman, George D.
supporting information; experimental part, p. 3129 - 3133 (2010/07/20)
Hit to lead optimization of (5R)-5-hexyl-3-phenyl-1,3-oxazolidin-2-one as a positive allosteric modulator of mGluR2 is described. Improvements in potency and metabolic stability were achieved through SAR on both ends of the oxazolidinone. An optimized lea
3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES
-
Page/Page column 56; 60-61, (2009/09/05)
The present invention is directed to 3,5-disubstituted-l,3-oxazolidin~2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psyc
